Floxin and arthralgia

The following are the known, listed and published adverse drug events associated with fluoroquinolone therapy. Floxin is a chemotherapuetic antibiotic belonging to this class:

Adverse effects related to fluoroquinolones
Asthenia

Edema

Fever

Malaise

Rigors

Substernal Chest Pain

Syncope

Cardiovascular Disorders

Cardiac Failure

Circulatory Failure

Hypertension

Central and Peripheral Nervous System Disorders

Abnormal Coordination

Coma

Convulsions

Seizures

Hyperkinesia

Hypertonia

Hypoaesthesia

Involuntary Muscle Contractions

Paresthesia

Paralysis

Speech Disorders

Stupor

Tremor

Vertigo

Gastrointestinal System Disorders

Dry Mouth

Dysphagia

Gastroenteritis

G.I.Hemorrhage

Pancreatitis

Pseudomembranous Colitis

Tongue Edema

Hearing and Vestibular Disorders

Ear Disorders

Tinnitus

Heart Rate and Rhythm Disorders

Arrhythmia

Atrial Fibrillation

Bradycardia

Cardiac Arrest

Heart Block

Palpitation

Supraventricular Tachycardia

Tachycardia

Ventricular Fibrillation

Hematology

Decreased Lymphocytes

Liver and Biliary System Disorders

Abnormal Hepatic Function

Cholelithiasis

Hepatic Coma

Jaundice

Metabolic and Nutritional Disorders

Aggravated Diabetes

Mellitus

Decreased Glucose

Decreased Magnesium

Increased Calcium

Dehydration

Hyperglycemia

Hyperkalemia

Hypoglycemia

Hypokalemia

Increased LDH

Weight Loss

Musculo-Skeletal System Disorders

Arthralgia

Arthritis

Arthrosis

Muscle Weakness

Myalgia

Osteromyelitis

Rhabdomyolysis

Synovitis

Tendinitis

Myo, Endo, Pericardial and Valve Disorders

Angina

Pectoris

Coronary Thrombosis

Myocardial Infarction

Neoplasms

Carcinoma

Parosmia

Platelet, Bleeding and Clotting Disorders

Abnormal Platelets

Embolism

Epistaxis

Purpura

Thrombocytopenia

Psychiatric Disorders

Abnormal Dreaming

Aggressive Reaction

Agitation

Anorexia

Anxiety

Confusion

Delirium

Depression

Emotional Liability

Hallucination

Impaired Concentration

Impotence

Manic Reaction

Mental Deficiency

Nervousness

Paranoia

Sleep Disorders

Somnolence

Withdrawal Syndrome

Suicide

Red Blood Cell Disorders

Anemia

Reproductive Disorders

Ejaculation Failure

Resistance Mechanism Disorders

Fungal Infections

Genital Moniliasis

Respiratory System Disorders

ARDS

Asthma

Coughing

Dyspnea

Haemoptysis

Hypoxia

Pleural Effusion

Respiratory Insufficiency

Respiratory Failure

Skin and Appendages Disorders

Erythema Nodosum

Genital Pruritus

Increased Sweating

Skin Disorders

Skin Exfoliation

Skin Ulceration

Urticaria

Urinary System Disorders

Abnormal Renal Function

Acute Renal Failure

Face Edema

Crystalluria

Cylindruria

Hematuria

Vascular (Extracardiac) Disorders

Cerebrovascular Disorder

Phlebitis

Vision Disorders

Abnormal Vision

Conjunctivitis

Diplopia

Retina Damage

Cornea Damage

Ophthalmologic Abnormalities

Cataracts

Multiple Punctate Lenticular Opacities

White Cell and RES Disorders

Granulocytopenia

Leukocytosis

Leukopenia

Lymphadenopathy

WBC Abnormal Count

Allergic Pneumonitis

Anaphylactic Shock

Anaphylactoid Reaction

Dysphonia

Abnormal EEG

Encephalopathy

Eosinophilia

Erythema Multiforme

Hemolytic Anemia

Multi System Organ Failure (Death)

Increased International Normalized Ratio (INR) Prothrombin Time

Stevens-Johnson Syndrome

Tendon Rupture

Torsades de Pointes

Vasodilation

This is but a small sampling of various adverse reactions associated with such therapy.

This list goes on and on and on and on and on. The physician has no clue as to what these drugs can and will do to a patient. There is no known treatment for a majority of the severe reactions. Such reactions DO NOT abate once therapy is discontinued in a subset of those so treated and the current research indicates that such events are to be considered permanent in nature.

David T Fuller
Director
Fluoroquinolone Toxicity Research Foundation
davidtfull@aol.com
www.fqresearch.org